ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00818389
Recruitment Status : Terminated (NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.)
First Posted : January 7, 2009
Results First Posted : April 19, 2011
Last Update Posted : April 19, 2011
Sponsor:
Collaborators:
ALS Association
ALS Society of Canada
National Institute of Neurological Disorders and Stroke (NINDS)
University of Toronto
State University of New York - Upstate Medical University
Columbia University
University of Kentucky
Information provided by:
Massachusetts General Hospital

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Lithium Carbonate
Drug: Riluzole
Drug: placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between January 2009 to June 2009, 97 patients were screened and 84 subjects were randomized at 21 clinical sites; 11 in the United States and 10 in Canada. All sites were members of the Northeast ALS Consortium (NEALS) and/or the Canadian ALS Consortium (CALS).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All patients were required to be on a stable dose of riluzole for at least 30 days prior to screening. 13 subjects failed screening: 3 due to low lung function test results, 3 due to prohibited medications,3 due to study closure, 2 due to abnormal lab test results and 1 due to death unrelated to the study.

Reporting Groups
  Description
Lithium + Riluzole Subjects randomized to lithium + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Lithium carbonate and matching placebo were supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule taken in the a.m. and 2 capsules taken in the p.m.), titrated to maintain plasma lithium levels of 0.4 - 0.8 milliequivalent per liter (mEq/L). The number of capsules taken per day was titrated individually for each patient based on blood testing to maintain plasma levels of lithium = 04. - 0.8 milliequivalent per liter (mEq/L).
Placebo + Riluzole Participants randomized to placebo + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Matching placebo was supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule in the a.m. and 2 capsules in the p.m). Paired sham dosage modifications were made for placebo subjects, i.e. all subjects randomized to placebo were 'paired' with a lithium subject and underwent identical dosage changes to maintain blinding.

Participant Flow:   Overall Study
    Lithium + Riluzole   Placebo + Riluzole
STARTED   40   44 
COMPLETED   36 [1]   38 [2] 
NOT COMPLETED   4   6 
Death                1                3 
ALS Disease Progression                1                0 
Withdrawal by Subject                2                2 
Adverse Event                0                1 
[1] 4 subjects terminated study early before 1st interim analysis. Study terminated early for futility.
[2] 6 subjects terminated study early before 1st interim analysis. Study terminated early for futility.



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lithium + Riluzole Subjects randomized to lithium + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Lithium carbonate and matching placebo were supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule taken in the a.m. and 2 capsules taken in the p.m.), titrated to maintain plasma lithium levels of 0.4 - 0.8 milliequivalent per liter (mEq/L). The number of capsules taken per day was titrated individually for each patient based on blood testing to maintain plasma levels of lithium = 04. - 0.8 milliequivalent per liter (mEq/L).
Placebo + Riluzole Participants randomized to placebo + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Matching placebo was supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule in the a.m. and 2 capsules in the p.m). Paired sham dosage modifications were made for placebo subjects, i.e. all subjects randomized to placebo were 'paired' with a lithium subject and underwent identical dosage changes to maintain blinding.
Total Total of all reporting groups

Baseline Measures
   Lithium + Riluzole   Placebo + Riluzole   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 40   44   84 
Age 
[Units: Years]
Mean (Standard Deviation) 		 58.3  (10.2)   55.5  (11.9)   56.24  (11.16) 
Gender 
[Units: Participants]
 		     
Female   10   20   30 
Male   30   24   54 
Ethnicity (NIH/OMB) 
[Units: Participants]
 		     
Hispanic or Latino   0   2   2 
Not Hispanic or Latino   40   42   82 
Unknown or Not Reported   0   0   0 
Race (NIH/OMB) 
[Units: Participants]
 		     
American Indian or Alaska Native   0   0   0 
Asian   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   1   2   3 
White   39   42   81 
More than one race   0   0   0 
Unknown or Not Reported   0   0   0 
ALS Functional Rating Scale-Revised (ALSFRS-R) [1] 
[Units: Scores on a scale]
Mean (Standard Deviation) 		 38.4  (4.6)   36.5  (5.7)   37.43  (5.24) 
[1] ALSFRS-R is an ordinal rating scale questionnaire (rating 0-4) used to determine subject's assessment of their capability and independence in 12 functional activities (i.e. this is a patient-reported questionnaire scale of disability). Each question has a rating of 0-4 with 4 being the most functional and 0 being the least functional. The most functional total score is 48.
Vital Capacity [1] 
[Units: Percent of predicted normal]
Mean (Standard Deviation) 		 94.0  (18.1)   86.9  (16.9)   90.18  (18.20) 
[1] Vital capacity (VC) testing is a measure of lung function that is performed using a standard spirometer and the Slow VC method. Three trials were required (5 maximum); the best of 3 was used.


  Outcome Measures

1.  Primary:   Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)   [ Time Frame: 9 months: Baseline to study termination (January 2009 - October 2009) ]
  Show Outcome Measure 1

2.  Secondary:   Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)   [ Time Frame: 9 months: Baseline to study termination (January 2009 - October 2009) ]
  Show Outcome Measure 2

3.  Secondary:   Vital Capacity (VC) (Percent of Predicted Normal)   [ Time Frame: 9 months: Baseline to study termination (January 2009- October 2009) ]
  Show Outcome Measure 3


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Elizabeth Simpson
Organization: Massachusetts General Hospital
phone: 617-726-3430
e-mail: esimpson1@partners.org


Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Merit Cudkowicz, MD, MSc, Co-Director, Neurology Clinical Trials Unit, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00818389     History of Changes
Other Study ID Numbers: U01NS049640 ( U.S. NIH Grant/Contract )
3U01NS049640-04S1 ( U.S. NIH Grant/Contract )
First Submitted: January 6, 2009
First Posted: January 7, 2009
Results First Submitted: May 10, 2010
Results First Posted: April 19, 2011
Last Update Posted: April 19, 2011